- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06062563
Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
An Exploratory Study to Evaluate the Efficacy of Anlotinib Hydrochloride Combined With Penpulimab in the Treatment of Radioiodine Refractory Differentiated Thyroid Cancer With First-line Resistance to Angiogenesis Inhibitors
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100007
- YansongLin
-
Contact:
- Yansong Lin, PhD
- Phone Number: 13671116837
- Email: linys@pumch.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients voluntarily joined the study, signed the informed consent;
- Patients were pathologically confirmed as locally advanced or metastatic differentiated thyroid cancer (DTC), having at least one measurable lesion (Response Evaluation Criteria In Solid Tumors (RECIST) 1.1);
- Patients≥18 years of age; Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score: 0-2; Expected survival of more than 6 months;
- Possessing imaging or clinical evidence of disease progression within the first 18 months of enrollment;
- Progression of at least one anti-vascular drug(no more than 2);
- Tg and structural imaging examinations were performed at least twice before enrollment;
- Meet any of the following while meeting the above 3 items:(1)Lesions were not iodine-avid;(2) The cumulative dose of RAI was ≥ 600 mCi or 22 GBq, with an interval of at least 3 months. (3) Radiographically documented disease progression within 18 months of RAI therapy despite the presence of iodine-131 affinity at the time of RAI therapy;
Major organ functions meet the following criteria within 7 days prior to the treatment:
- Hemoglobin (Hb) ≥90g/L;
- Absolute Neutrophil Count (ANC) ≥1.5×109/L;
- Platelet (PLT) ≥80×109/L;
- Total bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN);
- Alanine transferase (ALT) and Aspartate transferase (AST) ≤2.5×ULN; If accompanied by liver metastasis, ALT and AST ≤5×ULN; (f)Serum creatinine (Cr) ≤1.5×ULN or Creatinine clearance rate (CCr) ≥60ml/min; (g) The left ventricular ejection fraction was at least 50% of the normal level.
- Female patients of reproductive age should agree that birth control (such as intrauterine device, birth control pills, or condoms) must be used during the study period and for six months after completion; Having a negative serum pregnancy test within 7 days prior to study enrollment, and must be non-lactating; Male patients should agree to use contraception during the study period and for six months after the end of the study.
Exclusion Criteria:
Complicated diseases and history:
- Histologic subtypes of thyroid cancer other than the differentiated type (e.g., medullary carcinoma, lymphoma, or sarcoma) could not be enrolled; Patients currently have or had other malignancies within 5years. Cured localized tumors could be enrolled(e.g., Skin basal cell carcinoma)
Subjects with any severe and/or uncontrolled heart disease, including:
- According to the criteria of New York Heart Association (NYHA) grade II or above cardiac insufficiency or echocardiography: LVEF (left ventricular ejection fraction) <50%;
- Unstable angina
- A myocardial infarction had occurred within 1 year before the beginning of the treatment
- Clinically significant supraventricular or ventricular arrhythmias require treatment or intervention
- QTc ≥450ms (male), QTc ≥470ms (female) (classified by New York heart association, NYHA);
- Other anti-tumor treatment (including but not limited to chemotherapy, radiotherapy, etc.). were received within 28 days before the beginning of the treatment; TSH suppression therapy was excluded;
- Patients who have previously used immune checkpoint inhibitors (including but not limited to nivolumab, pembrolizumab, toripalimab, sintilimab, etc.);
5) Patients with hypertension that was not falling to the normal range with antihypertensive medication (systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg) were allowed to use antihypertensive treatment to achieve these parameters. Hypertensive crisis or hypertensive encephalopathy.
6) Multiple factors affect the absorption of oral drugs. 7)Patients at risk for gastrointestinal bleeding were not eligible, including the following: (1) patients with active peptic ulcer lesions and fecal occult blood (++); (2) patients with a history of melena and hematemesis within 3 months; 8). Active or uncontrolled severe infection (≥ Common Terminology Criteria for Adverse Events (CTC AE) 2 grade of infection); 9) Patients with concomitant diseases that, in the investigator's judgment, may seriously endanger patients' safety or may interfere with the completion of the study, or are deemed unsuitable for inclusion for other reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anlotinib+ penpulimab
Anlotinib:12 mg once daily for 2 weeks, followed by a rest of 1 week (21-day cycle); Penpulimab:200mg Q3 W
|
Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously. Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Baseline up to 2 years.
|
The proportion of subjects who achieves a best overall response of CR(Complete Response) or PR(Partial response).
|
Baseline up to 2 years.
|
changes in Tg level
Time Frame: Baseline up to 2 years.
|
The percentage of decrease in serum Tg from baseline;
|
Baseline up to 2 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response(DOR)
Time Frame: Baseline up to 2 years.
|
From the date that CR or PR are first occurred to the date of objective disease progression or death, whichever occurs first.
|
Baseline up to 2 years.
|
Progression-free Survival (PFS)
Time Frame: Baseline up to 2 years.
|
From the first dose of Anlotinib to the date of objective disease progression or death, whichever occurs first
|
Baseline up to 2 years.
|
Disease-control Rate(DCR)
Time Frame: Baseline up to 2 years.
|
The proportion of subjects response of CR, PR, or SD(Stable disease) (subjects achieving SD will be included in the DCR if they maintain SD for ≥4 weeks).
|
Baseline up to 2 years.
|
Overall Survival(OS)
Time Frame: Baseline up to 2 years.
|
From randomization to the time of death from any cause.
|
Baseline up to 2 years.
|
Time to response(TTR)
Time Frame: Baseline up to 2 years.
|
From randomization to the time of response from any cause.
|
Baseline up to 2 years.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- T004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
-
Providence Health & ServicesRecruitingBRAF V600E Mutation Present | Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 | Refractory Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | BRAF NP_004324.2:p.V600M | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IVB Differentiated Thyroid Gland Carcinoma...United States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
University of PennsylvaniaCompletedMetastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingPoorly Differentiated Thyroid Gland Carcinoma | Refractory Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Differentiated Thyroid Gland Carcinoma | Thyroid... and other conditionsUnited States
-
LetolabNot yet recruitingLocally Advanced or Metastatic CRC
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
Merck Sharp & Dohme LLCCompletedMetastatic or Locally Advanced Cancer
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
FutureGen Biopharmaceutical (Beijing) Co., LtdRecruitingLocally Advanced Unresectable or Metastatic Gastric Cancer | Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaChina
Clinical Trials on Anlotinib Hydrochloride Capsule and Penpulimab
-
Peking Union Medical College HospitalRecruiting
-
Peking University Third HospitalNot yet recruitingNon-Small Cell Lung Cancer
-
Hunan Cancer HospitalFuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...RecruitingSmall Cell Lung CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Hunan Cancer HospitalHenan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingNon Small Cell Lung CancerChina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingMGMT-Unmethylated GlioblastomaChina
-
The First Affiliated Hospital of Zhengzhou UniversityNot yet recruitingCervical Cancer
-
Zhongda HospitalRecruiting
-
The First Affiliated Hospital of Xinxiang Medical...RecruitingLung Cancer | Non Small Cell Lung Cancer | Lung Carcinoma | Non-small Cell Carcinoma | Lung NeoplasmChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting